GlassScriptPhysician profile
Dennis P Spratt
NPI 1679509236
$4,603.05
in general payments reported to CMS, 2019-2025
48 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $419 · 2021: $1,052 · 2022: $883 · 2023: $735 · 2024: $562 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $659.34 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $634.28 | 2021-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $409.21 | 2019-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $205.22 | 2020-2024 | Belsomra, Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.11 | 2019-2025 | Jardiance |
| Amgen INC. | $194.99 | 2020-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $189.56 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $172.41 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.09 | 2019-2024 | Xifaxan |
| Pfizer INC. | $154.90 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $146.72 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $114.32 | 2019-2022 | |
| Biogen, INC. | $99.03 | 2021-2025 | Zurzuvae |
| Astellas Pharma US INC | $88.52 | 2019-2023 | Myrbetriq |
| Glaxosmithkline, LLC. | $88.18 | 2019-2024 | Trelegy Ellipta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Spratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.